Nonpalpable prostate cancer detected in the prostate-specific antigen era H. Ballentine Carter Editorial Pages: 329 - 330
Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen Robert A. StephensonJanet L. Stanford OriginalPaper Pages: 331 - 335
Ultrasound findings are not useful for defining stage Tic prostate cancer Holt SandersRizk El-Galley OriginalPaper Pages: 336 - 338
Comparison of pathologic characteristics of T1c and non-Tic cancers detected in a population-based screening study, the European randomized study of screening for prostate cancer Robert F. HoedemaekerJohn B. W. RietbergenFritz H. Schröder OriginalPaper Pages: 339 - 345
Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy Mario C. BeduschiRicardo BeduschiJoseph E. Oesterling OriginalPaper Pages: 346 - 358
Prediction of significant cancer in men with stage Tic adenocarcinoma of the prostate H. Ballentine CarterJonathan I. Epstein OriginalPaper Pages: 359 - 363
Expectant management as an option for men with stage T1c prostate cancer: a preliminary study James L. MohlerBernadette T. WilliamsJ. L. Mohler OriginalPaper Pages: 364 - 368
Radiation therapy as treatment for stage T1c prostate cancers Gerald E. HanksAlexandra L. HanlonTimothy E. Schultheiss OriginalPaper Pages: 369 - 372
Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer Charles R. PoundPatrick C. WalshAlan W. Partin OriginalPaper Pages: 373 - 377
Advances in the evaluation and treatment of the infertile man Edward D. KimLarry I. Lipshultz Free paper Pages: 378 - 393